MedPath

Duloxetine

Generic Name
Duloxetine
Brand Names
Cymbalta, Drizalma, Irenka, Yentreve, Duloxetine Zentiva, Duloxetine Mylan, Duloxetine Lilly
Drug Type
Small Molecule
Chemical Formula
C18H19NOS
CAS Number
116539-59-4
Unique Ingredient Identifier
O5TNM5N07U
Background

Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.

Indication

Indicated for:

1) Management of Major Depressive Disorder.

2) Management of Generalized Anxiety Disorder.

3) Management of diabetic peripheral neuropathy.

4) Management of fibromyalgia.

5) Management of chronic musculoskeletal pain.

6) Management of osteoarthritis of the knee in adults.

7) Management of chronic lower back pain in adults.

8) Management of stress urinary incontinence in adult women.

Off-label uses include:

1) Management of chemotherapy-induced peripheral neuropathy.

2) Management of stress urinary incontinence in adult men after prostatectomy until recovery is complete.

Associated Conditions
Chronic Lower Back Pain (CLBP), Chronic Musculoskeletal Pain, Diabetic Peripheral Neuropathic Pain (DPN), Fibromyalgia, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Osteoarthritis of the Knee, Stress Urinary Incontinence (SUI)
Clinical Trials
Related News

Transneural Therapeutics Unveils Novel Non-Hallucinogenic Neuroplastogens for Neuropsychiatric Disorders

• Transneural Therapeutics has emerged from stealth mode with a preclinical pipeline of non-hallucinogenic neuroplastogens designed to treat neuropsychiatric and neurodegenerative diseases. • The company's lead candidate, TN-001, is a dual 5-HT2A partial agonist/5-HT2B antagonist engineered to deliver rapid antidepressant effects without hallucinations, targeting major depressive disorder and PTSD. • Industry veteran Charmaine Lykins, with 30 years of CNS drug development experience, will lead Transneural as CEO following its spin-out from CaaMTech.

FDA Approves Spravato (Esketamine) Nasal Spray as Standalone Treatment for Treatment-Resistant Depression

• The FDA has approved Spravato (esketamine) nasal spray as a monotherapy for adults with treatment-resistant depression (TRD). • Spravato demonstrated rapid and superior improvement in depressive symptoms compared to placebo in clinical trials. • The approval was based on a study where 22.5% of patients achieved remission with Spravato compared to 7.6% with placebo. • Due to risks, Spravato is only available through a restricted program under the supervision of a healthcare provider.

Xanomeline/Trospium Chloride Shows Cognitive Improvement in Schizophrenia; MindMed's LSD Trial Begins

• Xanomeline/trospium chloride (Cobenfy) improved cognition in schizophrenia patients with baseline cognitive impairment, according to an exploratory analysis of two phase III trials. • MindMed initiated a phase III trial of lysergide D-tartrate (LSD) for generalized anxiety disorder, marking the first phase III trial for LSD. • Reviva Pharmaceuticals reported that brilaroxazine significantly reduced PANSS total score in schizophrenia patients after 52 weeks in a long-term extension study. • A recall of over 230,000 bottles of duloxetine (Cymbalta) was initiated due to the potential presence of a carcinogen.

Tonix Pharmaceuticals' TNX-102 SL Awaits FDA Decision for Fibromyalgia Treatment

• Tonix Pharmaceuticals' TNX-102 SL, a non-opioid analgesic, has been assigned an FDA PDUFA goal date of August 15, 2025, for fibromyalgia treatment, potentially offering a new option for millions. • TNX-102 SL demonstrated significant pain reduction and improved sleep quality in Phase 3 trials, addressing key fibromyalgia symptoms with a well-tolerated safety profile. • The FDA previously granted Fast Track designation to TNX-102 SL, highlighting the urgent need for innovative treatments for fibromyalgia, a condition affecting mostly women. • If approved, TNX-102 SL could be the first in a new class of drugs for fibromyalgia in over 15 years, providing a novel approach to managing this chronic pain disorder.

Tonix Pharmaceuticals Seeks FDA Approval for TNX-102 SL in Fibromyalgia

• Tonix Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for TNX-102 SL, targeting sleep and pain relief in fibromyalgia patients. • Phase 3 trials demonstrated that TNX-102 SL significantly reduced daily pain and improved sleep quality compared to placebo in fibromyalgia patients. • TNX-102 SL has received Fast Track designation from the FDA, with a decision on potential marketing approval expected in 2025. • If approved, TNX-102 SL would be the first new drug in over 15 years for fibromyalgia, potentially benefiting millions of affected adults.

Tonix Pharmaceuticals Seeks FDA Approval for TNX-102 SL in Fibromyalgia

• Tonix Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for TNX-102 SL for the treatment of fibromyalgia. • TNX-102 SL, a non-opioid analgesic, has shown statistically significant pain reduction in two Phase 3 trials for fibromyalgia. • The FDA is expected to decide on the NDA acceptance in December 2024, with a potential approval decision in 2025. • Tonix is also advancing its mpox vaccine candidate, TNX-801, with new data demonstrating tolerability in immunocompromised animals.

MindMed to lead first LSD Phase 3 trials for anxiety - Drug Discovery and Development

Tonix Pharmaceuticals Submits NDA for TNX-102 SL for Fibromyalgia Treatment

• Tonix Pharmaceuticals has submitted an NDA to the FDA for TNX-102 SL, a non-opioid analgesic, seeking approval for fibromyalgia treatment. • TNX-102 SL demonstrated statistically significant pain reduction in two Phase 3 trials, offering a potential new option for fibromyalgia patients. • If approved, TNX-102 SL would be the first new drug for fibromyalgia in over 15 years, representing a novel tricyclic class of medicine. • The FDA has granted Fast Track designation to TNX-102 SL, with a PDUFA date expected in 2025 for a decision on approval.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy